The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human, open-label, phase I trial of daily oral PCLX-001, an NMT inhibitor, in patients with relapsed/refractory B-cell lymphomas and advanced solid tumors.
 
Randeep S. Sangha
Honoraria - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly; Merck; Pfizer; Roche/Genentech; Sanofi; Takeda; Teva
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly; Merck; Novartis; Roche/Genentech; Sanofi; Takeda; Teva; Teva
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Merck Serono (Inst); MorphoSys (Inst); Novartis (Inst); Pharmacyclics (Inst); Roche (Inst); Takeda (Inst)
 
Rahima Jamal
Consulting or Advisory Role - BMS
Research Funding - alkermes (Inst); Astellas Pharma (Inst); BioNTech SE (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pacylex (Inst); Pfizer (Inst); Surface Oncology (Inst); VelosBio/Merck (Inst)
 
Jennifer L. Spratlin
Honoraria - Celgene; Eisai; Lilly/ImClone; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - Astellas Oncology; Celgene; Eisai; Lilly/ImClone; Sanofi; Taiho Oncology
Research Funding - Celgene (Inst); Sanofi
 
John Kuruvilla
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Karyopharm Therapeutics; Merck; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Abbvie; Bristol Myers Squibb Foundation; Gilead Sciences; Karyopharm Therapeutics; Merck; Monte Rosa Therapeutics; Roche; Seagen
Research Funding - AstraZeneca; Merck; Roche
Other Relationship - Karyopharm Therapeutics
 
Laurie Helen Sehn
Honoraria - Abbvie; Amgen; AstraZeneca; BeiGene; Celgene/Bristol-Myers Squibb; Genmab; Gilead Sciences; Incyte; Janssen-Ortho; Kite, a Gilead company; Merck; Roche/Genentech; Sandoz-Novartis; Seagen; Teva
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Beigene; Celgene/Bristol-Myers Squibb; Genmab; Gilead Sciences; Incyte; Janssen; Kite, a Gilead company; Merck; Roche/Genentech; Sandoz-Novartis; Seagen; Teva; TG therapeutics
Research Funding - Roche/Genentech (Inst); Teva (Inst)
 
Michael Weickert
Employment - Pacylex
Leadership - Pacylex
Stock and Other Ownership Interests - Pacylex
Patents, Royalties, Other Intellectual Property - Pacylex
Travel, Accommodations, Expenses - Pacylex
 
Luc G. Berthiaume
Employment - Pacylex
Leadership - Pacylex
Stock and Other Ownership Interests - Pacylex
Patents, Royalties, Other Intellectual Property - Pacylex
Travel, Accommodations, Expenses - Pacylex
 
John Robert Mackey
Employment - Pacylex
Leadership - illumiSonics; Pacylex
Stock and Other Ownership Interests - illumiSonics; Pacylex
Consulting or Advisory Role - Fe Pharmaceuticals
Patents, Royalties, Other Intellectual Property - illumiSonics; Pacylex
Travel, Accommodations, Expenses - Pacylex